Print Icon

October 2022 Clinical Update: 

NCCN Guidelines for Treatment of Breast Cancer

The National Comprehensive Cancer Network (NCCN) Guidelines for Breast Cancer focus on screening, diagnosis, staging, treatment, and management. All breast cancer therapy regimens were categorized to provide guidance on treatment selection by considering the efficacy, safety, evidence, and other factors that play a role in treatment selection. These factors include comorbidities, nature of the disease, access to agents and hereditary genetic risk.

These updated guidelines include criteria for further genetic risk evaluation using a germline cancer panel for hereditary breast cancer syndromes:

·  Family history of known pathogenic variations or cancer,

·  Diagnosed before the age of 45,

·  Tumors with certain histological characteristics and location.

The panels are recommended to contain ATM, BRCA1, BRCA2, CHEK2, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, and TP53.

Genetics Institute of America’s GIAnomics™ Oncology Germline Panel includes all the recommended predisposition genes for breast cancer. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety.

Have you Seen This?: 

Psychosocial Implications of Germline Testing

One of the barriers to implementation for germline genetic testing into standard of care is the perceived notion that patients may have a negative emotional and social response to the results, especially in cases of high mortality. The National Comprehensive Cancer Network recommends germline testing for all ovarian cancer patients, pancreatic cancer patients and all breast cancer patients that meet guidelines. Read more >>

It's All in the Genes:

Germline Effects on Breast Cancer Treatment

Germline genetic testing can inform treatment decisions for breast cancer patients, but data has not been compiled about those treatment decisions. With an increase in testing, researchers and physicians want to further understand treatment trends, especially when considering surgery, radiation, and chemotherapy. Read more >>

Changing Corporate Culture:

4KIDS Celebrates 25 Years

Since 1997, 4KIDS has been one of the leading foster care agencies in South Florida, the Treasure Coast, Southwest Florida and the country. 4KIDS exists to bring hope, homes, and healing to kids and families in crisis across Florida. In partnership with local churches, businesses, and government agencies, 4KIDS is committed to redefining foster care in our community, one child at a time. Read more >>


Enroll your Practice in GH-101!

Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. 


Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.


Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP)

Laboratory Manager and Molecular Diagnostics Supervisor

Genetics Institute of America

GIA Lab News is an educational service of Genetics Institute of America.

Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases.

Follow Us On

4733 W. Atlantic Ave, Suite C16

Delray Beach, FL 33445

Phone: (833) 4GENLAB or (833) 443-6522

HIPAA Fax: (561) 354-5369

You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.

Who do you know that needs to know? Forward this email

Did someone forward this to you? Subscribe

Want to change how you receive these emails?

You can Unsubscribe or Update your preferences.

© 2022 Genetics Institute of America. All Rights Reserved.